Evidence map›Paper›PMID 34517466›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2021

[New development for targeted therapy of non-alcoholic fatty liver disease with thyroid hormone receptor beta].

B Y Cai, Y Y Hu, Q Feng

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Targeting THR-β for MASLD: Mechanisms and Drug Development.Drug design, development and therapy · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

B Y CaiShuguang Hospital & Institute of Hepatology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Y Y HuShuguang Hospital & Institute of Hepatology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China Key Laboratory of Liver and Kidney Diseaseas Ministry of Education, Shanghai 201203, China Shanghai Traditional Chinese Clinical Medicine, Shanghai 201203, China.
Q FengShuguang Hospital & Institute of Hepatology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China Key Laboratory of Liver and Kidney Diseaseas Ministry of Education, Shanghai 201203, China Shanghai Traditional Chinese Clinical Medicine, Shanghai 201203, China.
Shanghai University of Traditional Chinese Medicine · CN

Funding

National Natural Science Foundation of China 81830119National Science and Technology Major Project 'Key New Drug Creation and Manufacturing Program' 2019ZX09201001-001-002Shanghai Science and Technology Infrastructure Program 19401972100Shanghai Science and Technology Innovation Fund 18401933100
6 · The paper itself

Abstract

Non-alcoholic fatty liver disease has now become a common hepatic metabolic disease, but there is no universally approved therapeutic drug on the market, so there is an urgent need to explore relevant therapeutic drugs. Several studies have shown that the thyroid hormone receptor β, which is specifically expressed in the liver, plays an important role in lipid metabolism. T3 analogs and thyroid hormone receptor β-specific agonists have been developed for thyroid hormone receptor β. Many studies have shown that it can inhibit hepatic triglyceride synthesis, increase hepatic cholesterol clearance, reduce lipid deposition, and at the same time partly increase insulin sensitivity, promote glucose metabolism, and improve inflammation. Therefore, it has become a therapeutic drug with great potential for the treatment of non-alcoholic fatty liver disease. Herein, the mechanism, clinical research and drug development status are reviewed in order to provide new ideas for targeted therapy of non-alcoholic fatty liver disease with thyroid hormone receptor β.

Indexed as

Insulin ResistanceNon-alcoholic Fatty Liver DiseaseHumansLipid MetabolismThyroid Hormone Receptors betaThyroid Hormone Receptors betaAgonistsNonalcoholic fatty liver diseaseThyroid hormone receptor

Identifiers

PMID34517466
PMCPMC12814445
OpenAlexW3201196567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.